Lakewood-Amedex Biotherapeutics
LABT
6 hedge funds and large institutions have $307K invested in Lakewood-Amedex Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.13% more ownership
Funds ownership: 0% → 4.13% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marex Group
London,
|
+$826K |
| 2 |
HRT Financial
New York
|
+$768K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$70.3K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$10.7K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.37K |
Top Sellers
LABT Hedge Fund Activity: Q2 2026 in Review
6 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Lakewood-Amedex Biotherapeutics (LABT) for Q2 2026, worth a combined $307K.
Buyers outnumbered sellers: 6 funds opened new LABT positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $826K.
- 6 institutional investors held Lakewood-Amedex Biotherapeutics (LABT) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $307K of Lakewood-Amedex Biotherapeutics stock for Q2 2026.
- 6 funds opened new Lakewood-Amedex Biotherapeutics positions in Q2 2026 and 0 closed out, a net change of +6 holders.
- The largest Lakewood-Amedex Biotherapeutics buyer in Q2 2026 was Marex Group, an estimated $826K added.
Based on aggregated 13F filings for Q2 2026.